Nebenwirkungen · Temozolomide Teva
Temozolomide Teva 5 mg hard capsules Temozolomide Teva 20 mg hard capsules Temozolomide Teva 100 mg hard capsules Temozolomide Teva 140 mg hard capsules Temozolomide Teva 180 mg hard capsules Temozolomide Teva 250 mg hard capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-212065 · Präparat HOS-154816
Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19% and 17% respectively, of patients treated for malignant glioma. This led to hospitalisation and/or discontinuation of TMZ in 8% and 4%, respectively. Myelosuppression was predictable (usually within the first few cycles, with the nadir between Day 21 and Day 28), and recovery was rapid, usually within 1-2 weeks. No evidence of cumulative myelosuppression was observed. The presence of thrombocytopenia may increase the risk of bleeding, and the presence of neutropenia or leukopenia may increase the risk of infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-05-16T02:00:00Z · SHA-256 9c0a97d9d4d48622c8615e39cfac79b61fd65905543c5f50ba2ebfd2a591854a · Passage 745bae17fbc69f94e4783b1d5ce92f0c1591c62810a7661c27f0e0bf77adb3c1 · Zeichen 9928–10510 im Abschnitt